NO20021717L - Heterosyklisk natrium/proton utvekslingsinhibitorer og metode - Google Patents

Heterosyklisk natrium/proton utvekslingsinhibitorer og metode

Info

Publication number: NO20021717L
Authority: NO; Norway
Prior art keywords: proton exchange; exchange inhibitors; heterocyclic; sodium; heterocyclic sodium
Prior art date: 1999-10-12

Application number

NO20021717A

Other languages

English (en)

Norwegian (no)

Other versions

NO20021717D0 (no

Inventor

Saleem Ahmad

Shung C Wu

Steven V O'neil

Khehyoung Ngu

Karnail S Atwal

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-12

Filing date

2002-04-11

Publication date

2002-06-10

2002-04-11 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2002-04-11 Publication of NO20021717D0 publication Critical patent/NO20021717D0/no

2002-06-10 Publication of NO20021717L publication Critical patent/NO20021717L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Thiazole And Isothizaole Compounds (AREA)

NO20021717A 1999-10-12 2002-04-11 Heterosyklisk natrium/proton utvekslingsinhibitorer og metode NO20021717L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15875599P	1999-10-12	1999-10-12
PCT/US2000/027461 WO2001027107A2 (fr)	1999-10-12	2000-10-02	Inhibiteurs heterocycliques d'echange sodium / protons et procedes a cet effet

Publications (2)

Publication Number	Publication Date
NO20021717D0 NO20021717D0 (no)	2002-04-11
NO20021717L true NO20021717L (no)	2002-06-10

Family

ID=22569562

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20021717A NO20021717L (no)	1999-10-12	2002-04-11	Heterosyklisk natrium/proton utvekslingsinhibitorer og metode

Country Status (26)

Country	Link
US (2)	US6887870B1 (fr)
EP (1)	EP1224183B1 (fr)
JP (1)	JP2003527331A (fr)
KR (1)	KR20020038818A (fr)
CN (1)	CN1468232A (fr)
AR (1)	AR026023A1 (fr)
AT (1)	ATE314364T1 (fr)
AU (1)	AU7859600A (fr)
BR (1)	BR0014725A (fr)
CA (1)	CA2388813A1 (fr)
CO (1)	CO5251416A1 (fr)
DE (1)	DE60025245T2 (fr)
DK (1)	DK1224183T3 (fr)
ES (1)	ES2254236T3 (fr)
HK (1)	HK1045691A1 (fr)
HU (1)	HUP0300195A3 (fr)
IL (1)	IL148517A0 (fr)
MX (1)	MXPA02003626A (fr)
NO (1)	NO20021717L (fr)
NZ (1)	NZ517668A (fr)
PE (1)	PE20011001A1 (fr)
PL (1)	PL366131A1 (fr)
RU (1)	RU2002111867A (fr)
TR (1)	TR200201014T2 (fr)
WO (1)	WO2001027107A2 (fr)
ZA (1)	ZA200202479B (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030055026A1 (en)	2001-04-17	2003-03-20	Dey L.P.	Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en)	2001-04-17	2003-12-23	Dey, L.P.	Bronchodilating compositions and methods
EP1444981A1 (fr)	2001-10-11	2004-08-11	Katsuhiko Mikoshiba	Inhibiteurs de l'augmentation de la concentration du calcium intracellulaire
EP1465622A1 (fr) *	2001-11-26	2004-10-13	Arachnova Therapeutics Ltd.	Utilisation d'activateurs des ppar dans le traitement de fibrose pulmonaire
WO2004022536A1 (fr) *	2002-09-04	2004-03-18	Glenmark Pharmaceuticals Limited	Nouveaux composes amides heterocycliques utilises pour le traitement d'affections inflammatoires et allergiques; procede permettant de les fabriquer et compositions pharmaceutiques les contenant
US7238725B2 (en)	2002-10-23	2007-07-03	Glenmark Pharmaceuticals Ltd.	Tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
ES2305520T3 (es)	2002-11-18	2008-11-01	Novartis Ag	Derivados de imidazo(1,5a)piridina y metodos para tratar enfermedades mediadas por aldosterona.
ATE374766T1 (de) *	2003-01-14	2007-10-15	Arena Pharm Inc	1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
EP1927594A1 (fr) *	2003-01-14	2008-06-04	Arena Pharmaceuticals, Inc.	Dérivés d'aryle et d'hétéroaryle 1,2,3-trisubstitués en tant que modulateurs du métabolisme et la prévention et le traitement de maladies liées à celui-ci, telles que le diabète et l'hyperglycémie
DK1620429T3 (da)	2003-04-11	2009-05-18	Glenmark Pharmaceuticals Sa	Nye heterocykliske forbindelser anvendelige til behandling af inflammatoriske og allergiske sygdomme, fremgangsmåder til deres fremstilling og farmaceutiske sammensætninger indeholdende disse
EP1862181A3 (fr) *	2003-04-11	2010-09-15	High Point Pharmaceuticals, LLC	Polythérapie utilisant un inhibiteur de la 11B-hydroxystéroïde déshydrogénase de type 1 et agent anti-hypertensif pour le traitement du syndrome métabolique et maladies et troubles associés
AU2003901812A0 (en) *	2003-04-15	2003-05-01	Vital Health Sciences Pty Ltd	Phosphates of secondary alcohols
JP4499106B2 (ja) *	2003-05-29	2010-07-07	メルク・シャープ・エンド・ドーム・コーポレイション	１１−ベータ−水酸化ステロイド脱水素酵素−１の阻害剤としてのトリアゾール誘導体
GB0315950D0 (en)	2003-06-11	2003-08-13	Xention Discovery Ltd	Compounds
TWI359675B (en)	2003-07-10	2012-03-11	Dey L P	Bronchodilating β-agonist compositions
AR045047A1 (es) *	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AU2004257267B2 (en)	2003-07-14	2009-12-03	Arena Pharmaceuticals,Inc	Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
ATE430741T1 (de)	2003-07-24	2009-05-15	Euro Celtique Sa	Piperidinverbindungen und pharmazeutische zusammensetzungen, die diese enthalten
US8455489B2 (en) *	2003-11-10	2013-06-04	Exelixis, Inc.	Substituted pyrimidine compositions and methods of use
US8519158B2 (en)	2004-03-12	2013-08-27	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
GB0412986D0 (en)	2004-06-10	2004-07-14	Xention Discovery Ltd	Compounds
WO2006040652A2 (fr)	2004-10-13	2006-04-20	Glenmark Pharmaceuticals S.A.	Procede de preparation de n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide
US7576212B2 (en)	2004-12-09	2009-08-18	Xention Limited	Thieno[2,3-B] pyridines as potassium channel inhibitors
CA2591438C (fr)	2004-12-17	2014-04-29	Glenmark Pharmaceuticals S.A.	Nouveaux composes heterocycliques utiles pour le traitement de troubles inflammatoires et allergiques
PT1831227E (pt)	2004-12-17	2013-08-23	Glenmark Pharmaceuticals Sa	Proteínas buganina modificadas, citotoxinas e métodos e utilizações das mesmas
ATE412647T1 (de)	2005-05-13	2008-11-15	Lilly Co Eli	Substituierte n-arylpyrrolidine als selektive modulatoren des androgenrezeptors
GB0525164D0 (en)	2005-12-09	2006-01-18	Xention Discovery Ltd	Compounds
KR20090130422A (ko)	2007-04-27	2009-12-23	퍼듀 퍼머 엘피	통증 치료에 유용한 치료제
PE20090422A1 (es)	2007-04-27	2009-04-18	Purdue Pharma Lp	Derivados de piperidina, piperazina o tetrahidropiridilo como antagonistas de trpv1
CN101679191B (zh)	2007-06-05	2014-03-12	塞诺菲-安万特股份有限公司	二杂芳基环己烷衍生物、其制备方法、用途及含有它们的药用组合物
GB0818241D0 (en) *	2008-10-06	2008-11-12	Cancer Res Technology	Compounds and their use
US8703962B2 (en) *	2008-10-24	2014-04-22	Purdue Pharma L.P.	Monocyclic compounds and their use as TRPV1 ligands
US8759362B2 (en) *	2008-10-24	2014-06-24	Purdue Pharma L.P.	Bicycloheteroaryl compounds and their use as TRPV1 ligands
WO2018129556A1 (fr)	2017-01-09	2018-07-12	Ardelyx, Inc.	Composés et procédés pour l'inhibition d'un antiport à médiation par échangeur sodium/proton (nhe) dans le traitement de troubles associés à une rétention d'eau ou à une surcharge en sel et de troubles du tractus gastro-intestinal
KR101683318B1 (ko)	2008-12-31	2016-12-07	알데릭스, 인코포레이티드	체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
EP2585446A4 (fr)	2010-06-22	2013-12-25	Shionogi & Co	Composés présentant une activité antagoniste des trpv1 et leurs utilisations
CN103221410B (zh)	2010-09-22	2017-09-15	艾尼纳制药公司	Gpr119受体调节剂和对与其相关的障碍的治疗
GB201105659D0 (en)	2011-04-01	2011-05-18	Xention Ltd	Compounds
BR112013030442B1 (pt) *	2011-06-10	2021-11-09	Merck Patent Gmbh	Compostos de pirimidina e piridina com atividade inibidora de btk, seus usos, composição, e kit
UA113288C2 (xx)	2011-06-22	2017-01-10		Trpv1 антагоністи, що містять дигідроксизамісник, і їх застосування
WO2013021276A1 (fr)	2011-08-10	2013-02-14	Purdue Pharma L.P.	Antagonistes du trpv1 comprenant un substituant dihydroxy et leurs utilisations
AR090037A1 (es)	2011-11-15	2014-10-15	Xention Ltd	Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
US8765959B2 (en) *	2011-12-23	2014-07-01	Boehringer Ingelheim International Gmbh	Piperidine derivatives
AR090880A1 (es) *	2012-04-30	2014-12-10	Janssen R & D Ireland	Derivados de pirimidina
PE20142366A1 (es) *	2012-05-30	2015-01-10	Hoffmann La Roche	Compuestos triazolo como inhibidores de pde 10
WO2014010748A1 (fr) *	2012-07-10	2014-01-16	Shionogi & Co., Ltd.	Dérivé de cyclopropane présentant une activité inhibitrice de bace1
JP6009851B2 (ja) *	2012-07-27	2016-10-19	日本曹達株式会社	１ｈ−テトラゾール誘導体の製造方法
CA2880338A1 (fr)	2012-08-21	2014-02-27	Ardelyx, Inc.	Composes et procedes d'inhibition d'un antiport a mediation par nhe dans le traitement de troubles associes a une retention de fluide ou a une surcharge de sel et de troubles du tractus gastro-intestinal
US10376481B2 (en)	2012-08-21	2019-08-13	Ardelyx, Inc.	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
KR20210117282A (ko)	2013-04-12	2021-09-28	알데릭스, 인코포레이티드	Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법
AU2016205361C1 (en)	2015-01-06	2021-04-08	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the S1P1 receptor
PT3310760T (pt)	2015-06-22	2022-11-10	Arena Pharm Inc	Sal cristalino de l-arginina de ácido (r)-2-(7-(4-ciclopentil-3-(trifluorometil)benziloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para utilização em distúrbios associados a recetores de s1p1
MD3433234T2 (ro)	2016-03-22	2022-02-28	Merck Sharp & Dohme	Modulatori alosterici ai receptorilor nicotinici de acetilcolină
AU2017257377B2 (en) *	2016-04-29	2022-06-23	Iomet Pharma Ltd.	Novel substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase
KR20240090875A (ko)	2017-01-09	2024-06-21	알데릭스, 인코포레이티드	위장관 장애를 치료하는 데 유용한 화합물
US11147884B2 (en)	2017-01-09	2021-10-19	Ardelyx, Inc.	Inhibitors of NHE-mediated antiport
MA47504A (fr)	2017-02-16	2019-12-25	Arena Pharm Inc	Composés et méthodes de traitement de l'angiocholite biliaire primitive
WO2018149940A1 (fr)	2017-02-17	2018-08-23	Quimica Sintetica, S. A.	Procédé de préparation de dihydrobenzofuranes enrichis de manière énantiomérique et composés intermédiaires obtenus durant le procédé
WO2018224455A1 (fr)	2017-06-07	2018-12-13	Basf Se	Dérivés de cyclopropyle substitués
WO2018234488A1 (fr)	2017-06-23	2018-12-27	Basf Se	Dérivés de cyclopropyle substitués
IL318937A (en)	2017-08-04	2025-04-01	Ardelyx Inc	History of glycyrrhetinic acid for the treatment of hyperkalemia
WO2019121143A1 (fr)	2017-12-20	2019-06-27	Basf Se	Dérivés de cyclopropyle substitués
EP3743063A4 (fr) *	2018-01-26	2021-10-20	Nurix Therapeutics, Inc.	Inhibiteurs de cbl-b et leurs procédés d'utilisation
US10730874B2 (en)	2018-03-13	2020-08-04	Shire Human Genetic Therapies, Inc.	Inhibitors of plasma kallikrein and uses thereof
AU2019280822A1 (en)	2018-06-06	2021-01-07	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the S1P1 receptor
EP4234016B1 (fr)	2019-02-07	2025-06-18	Ardelyx, Inc.	Dérivés d'acide glycyrrhétinique destinés à être utilisés dans le traitement de l'hyperkaliémie
BR112021019722A2 (pt)	2019-04-09	2021-12-14	Nurix Therapeutics Inc	Compostos de piperidina 3-substituídos para inibição de cbl-b, e uso de inibidor de cbl-b em combinação com vacina contra câncer e/ou vírus oncolítico
MX2021012690A (es)	2019-04-19	2022-01-31	Ligand Pharm Inc	Formas cristalinas y metodos para producir formas cristalinas de un compuesto.
CN114340631A (zh)	2019-05-21	2022-04-12	阿德利克斯股份有限公司	用于降低患者的血清磷酸盐的组合
ES2987744T3 (es)	2019-09-18	2024-11-18	Takeda Pharmaceuticals Co	Inhibidores de calicreína plasmática y usos de los mismos
EP4031245A1 (fr)	2019-09-18	2022-07-27	Takeda Pharmaceutical Company Limited	Inhibiteurs hétéroaryles de la kallicréine plasmatique
US20230382891A1 (en) *	2020-10-20	2023-11-30	Blacksmith Medicines, Inc.	Glutaminyl-peptide cyclotransferase like (qpctl) protein inhibitors and uses thereof
EP4308228A1 (fr) *	2021-03-17	2024-01-24	Takeda Pharmaceutical Company Limited	Inhibiteurs de la kallicréine plasmatique

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1206498B (it)	1983-07-18	1989-04-27	Angeli Inst Spa	Derivati amidinici del4-fenilmidazolo 2-sostituto processi per la loro preparazione e loro uso farmaceutico.
FR2579596B1 (fr) *	1985-03-26	1987-11-20	Inst Nat Sante Rech Med	(imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
IT1201454B (it) *	1985-08-19	1989-02-02	Boehringer Biochemia Srl	1,4-diidropiridine-2-sostituite
US4663473A (en) *	1986-08-25	1987-05-05	The United States Of America As Represented By The Secretary Of The Army	Isocyanates from oxalyl chloride and amines
FR2674855B1 (fr) *	1991-04-03	1994-01-14	Synthelabo	Derives de piperidine, leur preparation et leur application en therapeutique.
US5380858A (en) *	1992-04-01	1995-01-10	The University Of Toledo	Process for the preparation of intermediates useful for the synthesis of histamine receptor antagonists
FR2696177B1 (fr) *	1992-09-28	1995-05-12	Synthelabo	Dérivés de pipéridine, leur préparation et leur application en thérapeutique.
JP4169368B2 (ja) *	1996-01-15	2008-10-22	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	脈管形成阻害性ピリダジンアミン
FR2765221B1 (fr)	1997-06-25	1999-07-30	Synthelabo	Derives de 4-[(1h-imidazol-4-yl)piperidin-1-yl]anilide, leur preparation et leur application en therapeutique
FR2765580B1 (fr)	1997-07-01	1999-08-06	Synthelabo	Derives de (1h-imidazol-4-yl)piperidine, leur preparation et leur application en therapeutique
FR2772377B1 (fr) *	1997-12-12	2000-01-07	Synthelabo	Derives de 1-(1-h-imidazol-2-yl)pyrrolidines et 1-(1-h-imidazol-2-ylpiperidines), leur preparation et leur application en therapeutique
US6011059A (en) *	1997-12-24	2000-01-04	Bristol-Myers Squibb Company	Acyl guanidine sodium/proton exchange inhibitors and method
EP1136489A1 (fr) *	2000-03-23	2001-09-26	Sanofi-Synthelabo	Dérivés de 2-[pipéridinyl]pyrimidinone

2000
- 2000-09-25 US US09/669,298 patent/US6887870B1/en not_active Expired - Lifetime
- 2000-10-02 KR KR1020027004653A patent/KR20020038818A/ko not_active Withdrawn
- 2000-10-02 IL IL14851700A patent/IL148517A0/xx unknown
- 2000-10-02 AU AU78596/00A patent/AU7859600A/en not_active Abandoned
- 2000-10-02 DE DE60025245T patent/DE60025245T2/de not_active Expired - Lifetime
- 2000-10-02 BR BR0014725-7A patent/BR0014725A/pt not_active IP Right Cessation
- 2000-10-02 ES ES00968723T patent/ES2254236T3/es not_active Expired - Lifetime
- 2000-10-02 NZ NZ517668A patent/NZ517668A/en unknown
- 2000-10-02 EP EP00968723A patent/EP1224183B1/fr not_active Expired - Lifetime
- 2000-10-02 HK HK02107204.5A patent/HK1045691A1/zh unknown
- 2000-10-02 HU HU0300195A patent/HUP0300195A3/hu unknown
- 2000-10-02 WO PCT/US2000/027461 patent/WO2001027107A2/fr not_active Ceased
- 2000-10-02 CA CA002388813A patent/CA2388813A1/fr not_active Abandoned
- 2000-10-02 PL PL00366131A patent/PL366131A1/xx unknown
- 2000-10-02 DK DK00968723T patent/DK1224183T3/da active
- 2000-10-02 JP JP2001530325A patent/JP2003527331A/ja not_active Withdrawn
- 2000-10-02 CN CNA008140626A patent/CN1468232A/zh active Pending
- 2000-10-02 TR TR2002/01014T patent/TR200201014T2/xx unknown
- 2000-10-02 AT AT00968723T patent/ATE314364T1/de active
- 2000-10-02 MX MXPA02003626A patent/MXPA02003626A/es unknown
- 2000-10-02 RU RU2002111867/04A patent/RU2002111867A/ru not_active Application Discontinuation
- 2000-10-10 PE PE2000001081A patent/PE20011001A1/es not_active Application Discontinuation
- 2000-10-10 CO CO00077054A patent/CO5251416A1/es not_active Application Discontinuation
- 2000-10-12 AR ARP000105372A patent/AR026023A1/es not_active Application Discontinuation
2002
- 2002-03-27 ZA ZA200202479A patent/ZA200202479B/xx unknown
- 2002-04-11 NO NO20021717A patent/NO20021717L/no not_active Application Discontinuation
2005
- 2005-01-31 US US11/046,993 patent/US7326705B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DK1224183T3 (da)	2006-03-06
US20050137216A1 (en)	2005-06-23
EP1224183B1 (fr)	2005-12-28
IL148517A0 (en)	2002-09-12
WO2001027107A3 (fr)	2002-01-24
AR026023A1 (es)	2002-12-26
PE20011001A1 (es)	2001-11-25
HUP0300195A2 (hu)	2003-07-28
HK1045691A1 (zh)	2002-12-06
US6887870B1 (en)	2005-05-03
TR200201014T2 (tr)	2003-01-21
DE60025245D1 (de)	2006-02-02
AU7859600A (en)	2001-04-23
ES2254236T3 (es)	2006-06-16
NZ517668A (en)	2004-09-24
EP1224183A2 (fr)	2002-07-24
ATE314364T1 (de)	2006-01-15
US7326705B2 (en)	2008-02-05
NO20021717D0 (no)	2002-04-11
KR20020038818A (ko)	2002-05-23
DE60025245T2 (de)	2006-08-24
WO2001027107A2 (fr)	2001-04-19
ZA200202479B (en)	2004-10-27
BR0014725A (pt)	2003-06-17
CO5251416A1 (es)	2003-02-28
RU2002111867A (ru)	2004-05-10
HUP0300195A3 (en)	2003-09-29
PL366131A1 (en)	2005-01-24
JP2003527331A (ja)	2003-09-16
CN1468232A (zh)	2004-01-14
CA2388813A1 (fr)	2001-04-19
MXPA02003626A (es)	2003-09-22

Publication	Publication Date	Title
NO20021717D0 (no)	2002-04-11	Heterocykliske natrium/proton utvekslingsinhibitorer og metode
NO20014823D0 (no)	2001-10-04	Heterocyklus-holdige bifenyl-aP2-inhibitorer og metode
DK1133477T3 (da)	2004-06-21	Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
EE200000610A (et)	2002-04-15	p38 heterotsüklilised inhibiitorid
NO20013452D0 (no)	2001-07-12	Benzoheterocykler og deres anvendelse som MEK-inhibitorer
IS6385A (is)	2002-05-15	Ný notkun og nýjar N-asabísýkló-amíð afleiður
NO20022086L (no)	2002-06-24	Antidiabetisk formulering og fremgangsmåte
DK1454907T3 (da)	2009-03-09	Quninazolin og pyridopyrmidin-derivativer
DE60008527D1 (de)	2004-04-01	Zellproliferation inhibitoren
NO20022656L (no)	2002-08-06	Caspaseinhibitorer og anvendelse derav
IS6934A (is)	2003-08-29	Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DK1177178T3 (da)	2005-05-02	Heterocyclisk substituerede benzimidazoler, deres fremstilling og anvendelse
NO20012688D0 (no)	2001-05-31	Benzamidderivater og anvendelse derav som APOB-100 sekresjonsinhibitorer
ATE231132T1 (de)	2003-02-15	Heterocyclische metalloprotease inhibitoren
NO20032668D0 (no)	2003-06-12	Gyraseinhibitorer og anvendelser derav
DK1251848T3 (da)	2004-10-18	Gyraseinhibitorer og anvendelse deraf
ATE226573T1 (de)	2002-11-15	Heterozyklische metalloproteaseinhibitoren
NO20005400D0 (no)	2000-10-26	Kinoloner anvendt som MRS-inhibitorer og baktericider
NO20000188D0 (no)	2000-01-14	Fremgangsmåte og anordning for sidebroenntilknytning
NO20013318L (no)	2001-08-30	Substituerte 2-aryliminoheterocykliske forbindelser og preparater inneholdende disse for anvendelse
NO20022853D0 (no)	2002-06-14	System og fremgangsmåte for multiprosessorforvaltning
NO20010405D0 (no)	2001-01-23	Pyrazolderivater og salter derav
NO20001718D0 (no)	2000-04-03	Benzen-fusjonerte heterocykliske derivater og anvendelse derav
DK1228026T3 (da)	2004-04-05	15-Hydroxyicosatetraensyrerelaterede forbindelser og fremgangsmåde til anvendelse
NO20000053L (no)	2000-07-10	FremgangsmÕte til dataoverføring

Legal Events

Date	Code	Title	Description
2006-03-20	FC2A	Withdrawal, rejection or dismissal of laid open patent application